Literature DB >> 24014509

Clinical trials in rare disease: challenges and opportunities.

Erika F Augustine1, Heather R Adams, Jonathan W Mink.   

Abstract

The neuronal ceroid lipofuscinoses constitute one of many groups of rare childhood diseases for which disease-modifying treatments are nonexistent. Disease-specific barriers to therapeutic success include incomplete understanding of disease pathophysiology and limitations of treatments that cannot adequately cross the blood-brain barrier to access the central nervous system. Therapeutic development in the neuronal ceroid lipofuscinoses shares many challenges with other rare diseases, such as incomplete understanding of natural history to inform trial design, need for alternatives to the randomized controlled clinical trial, requirement for more sensitive outcome measures to quantify disease, limited access to resources required to mount a clinical trial (including funding), and difficulties of recruiting a small sample to participation. Solutions to these barriers will require multicenter collaboration, partnership with patient organizations, training a new generation of researchers interested in rare diseases, and leveraging existing resources.

Entities:  

Keywords:  Batten disease; clinical trials; lysosomal storage disease; neuronal ceroid lipofuscinosis; rare disease

Mesh:

Year:  2013        PMID: 24014509      PMCID: PMC3964003          DOI: 10.1177/0883073813495959

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  73 in total

1.  Emerging subspecialties in neurology: fellowship in experimental therapeutics of neurologic disease.

Authors:  Jeffrey M Statland; Robert C Griggs; Erika F Augustine
Journal:  Neurology       Date:  2012-09-25       Impact factor: 9.910

2.  Epilepsy and antiepileptic drug therapy in juvenile neuronal ceroid lipofuscinosis.

Authors:  L E Aberg; M Bäckman; E Kirveskari; P Santavuori
Journal:  Epilepsia       Date:  2000-10       Impact factor: 5.864

3.  Enzyme replacement therapy in Fabry disease: a randomized controlled trial.

Authors:  R Schiffmann; J B Kopp; H A Austin; S Sabnis; D F Moore; T Weibel; J E Balow; R O Brady
Journal:  JAMA       Date:  2001-06-06       Impact factor: 56.272

4.  New antidepressive and antipsychotic drugs in juvenile neuronal ceroid lipofuscinoses--a pilot study.

Authors:  M L Bäckman; L E Aberg; E T Aronen; P R Santavuori
Journal:  Eur J Paediatr Neurol       Date:  2001       Impact factor: 3.140

5.  Aminoglycoside-mediated suppression of nonsense mutations in late infantile neuronal ceroid lipofuscinosis.

Authors:  D E Sleat; I Sohar; R M Gin; P Lobel
Journal:  Eur J Paediatr Neurol       Date:  2001       Impact factor: 3.140

6.  A favorable response to antiparkinsonian treatment in juvenile neuronal ceroid lipofuscinosis.

Authors:  L E Aberg; J O Rinne; I Rajantie; P Santavuori
Journal:  Neurology       Date:  2001-05-08       Impact factor: 9.910

7.  Selenium treatment in neuronal ceroid-lipofuscinosis.

Authors:  S Naidu; I Maumanee; J Olson; J Borel; H Moser
Journal:  Am J Med Genet Suppl       Date:  1988

8.  Therapeutic modification of membrane lipid abnormalities in juvenile neuronal ceroid-lipofuscinosis (Batten disease).

Authors:  M J Bennett; G P Hosking; R Gayton; G Thompson; J H Galloway; I J Cartwright
Journal:  Am J Med Genet Suppl       Date:  1988

9.  Clinico-pathological variability in the childhood neuronal ceroid-lipofuscinoses and new observations on glycoprotein abnormalities.

Authors:  K E Wisniewski; I Rapin; J Heaney-Kieras
Journal:  Am J Med Genet Suppl       Date:  1988

10.  Comparison of the clinical courses in patients with juvenile neuronal ceroid lipofuscinosis receiving antioxidant treatment and those without antioxidant treatment.

Authors:  P Santavuori; H Heiskala; T Autti; E Johansson; T Westermarck
Journal:  Adv Exp Med Biol       Date:  1989       Impact factor: 2.622

View more
  62 in total

1.  Effect of Mexiletine on Muscle Stiffness in Patients With Nondystrophic Myotonia Evaluated Using Aggregated N-of-1 Trials.

Authors:  Bas C Stunnenberg; Joost Raaphorst; Hans M Groenewoud; Jeffrey M Statland; Robert C Griggs; Willem Woertman; Dick F Stegeman; Janneke Timmermans; Jaya Trivedi; Emma Matthews; Christiaan G J Saris; Bas J Schouwenberg; Gea Drost; Baziel G M van Engelen; Gert Jan van der Wilt
Journal:  JAMA       Date:  2018-12-11       Impact factor: 56.272

Review 2.  Collaboration in Regulatory Science to Facilitate Therapeutic Development for Neonates.

Authors:  Susan K McCune; Yeruk Ager Mulugeta; Gerri R Baer
Journal:  Curr Pharm Des       Date:  2017       Impact factor: 3.116

Review 3.  Orphan drug development: the increasing role of clinical pharmacology.

Authors:  Mariam A Ahmed; Malek Okour; Richard Brundage; Reena V Kartha
Journal:  J Pharmacokinet Pharmacodyn       Date:  2019-07-23       Impact factor: 2.745

4.  Batten disease: an expert update on agents in preclinical and clinical trials.

Authors:  Margaux C Masten; Jonathan W Mink; Erika F Augustine
Journal:  Expert Opin Investig Drugs       Date:  2020-11-01       Impact factor: 6.206

5.  An Official American Thoracic Society Workshop Report: Translational Research in Rare Respiratory Diseases.

Authors:  Arnold S Kristof; Basil J Petrof; Qutayba Hamid; Martin Kolb; Jennifer S Landry; Alex MacKenzie; Francis X McCormack; Inga J Murawski; Joel Moss; Frank Rauch; Ivan O Rosas; Adam J Shapiro; Benjamin M Smith; David Y Thomas; Bruce C Trapnell; Lisa R Young; Maimoona A Zariwala
Journal:  Ann Am Thorac Soc       Date:  2017-08

6.  Editorial to the themed issue on application of pharmacometrics to the development of drugs for rare diseases.

Authors:  Peter Bonate
Journal:  J Pharmacokinet Pharmacodyn       Date:  2019-09-27       Impact factor: 2.745

7.  Quantifying the bias due to observed individual confounders in causal treatment effect estimates.

Authors:  Layla Parast; Beth Ann Griffin
Journal:  Stat Med       Date:  2020-05-10       Impact factor: 2.373

8.  Short-Term Administration of Mycophenolate Is Well-Tolerated in CLN3 Disease (Juvenile Neuronal Ceroid Lipofuscinosis).

Authors:  Erika F Augustine; Christopher A Beck; Heather R Adams; Sara Defendorf; Amy Vierhile; Derek Timm; Jill M Weimer; Jonathan W Mink; Frederick J Marshall
Journal:  JIMD Rep       Date:  2018-06-20

9.  Palivizumab prophylaxis for respiratory syncytial virus in infants with cystic fibrosis: is there a need?

Authors:  Candice Bjornson; Parco Chan; Abby Li; Bosco Paes; Krista L Lanctôt; Ian Mitchell
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-03-19       Impact factor: 3.267

10.  Neurocognitive clinical outcome assessments for inborn errors of metabolism and other rare conditions.

Authors:  Elsa Shapiro; Jessica Bernstein; Heather R Adams; Ann J Barbier; Teresa Buracchio; Peter Como; Kathleen A Delaney; Florian Eichler; Jonathan C Goldsmith; Melissa Hogan; Sarrit Kovacs; Jonathan W Mink; Joanne Odenkirchen; Melissa A Parisi; Alison Skrinar; Susan E Waisbren; Andrew E Mulberg
Journal:  Mol Genet Metab       Date:  2016-04-14       Impact factor: 4.797

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.